Abnormal alpha-synuclein (a-synuclein) expression and aggregation is a key characteristic of Parkinson's disease (PD). However, the exact mechanism(s) linking a-synuclein to the other central feature of PD, dopaminergic neuron loss, remains unclear. Therefore, improved cell and in vivo models are needed to investigate the role of a-synuclein in dopaminergic neuron loss. MicroRNA-7 (miR-7) regulates a-synuclein expression by binding to the 3 0 UTR of the Synuclein Alpha Non A4 Component of Amyloid Precursor (SNCA) gene and inhibiting its translation. We show that miR-7 is decreased in the substantia nigra of patients with PD and, therefore, may play an essential role in the regulation of a-synuclein expression. Furthermore, we have found that lentiviral-mediated expression of miR-7 complementary binding sites to stably induce a loss of miR-7 function results in an increase in a-synuclein expression in vitro and in vivo. We have also shown that depletion of miR-7 using a miR-decoy produces a loss of nigral dopaminergic neurons accompanied by a reduction of striatal dopamine content. These data suggest that miR-7 has an important role in the regulation of a-synuclein and dopamine physiology and may provide a new paradigm to study the pathology of PD.
INTRODUCTION
Abnormal expression and aggregation of the alpha-synuclein (a-synuclein) protein is known to play an important role in the pathogenesis of Parkinson's disease (PD). Missense mutations and locus multiplications in the SNCA gene, which encodes the protein a-synuclein, have been found to cause familial forms of PD. [1] [2] [3] [4] [5] Genome-wide association studies (GWAS) have shown that polymorphisms in the SNCA gene are risk factors for developing sporadic PD, [6] [7] [8] [9] and aggregated a-synuclein is the main component of Lewy bodies, the protein inclusions prevalent in the brains of patients with PD. 10 Furthermore, overexpression of a-synuclein has been found to be toxic to dopaminergic neurons, implicating a-synuclein as a key player in the molecular mechanisms of the disease. [11] [12] [13] [14] The mechanisms underlying a-synuclein toxicity are unclear, but one hypothesis is that a-synuclein may be acting in the manner of a prion:
transferring from cell to cell, thus spreading pathology. Braak and colleagues 15 were the first to suggest that a-synuclein might be spreading throughout the brain with Lewy pathology first appearing in the dorsal motor nucleus of the vagal nerve and the olfactory bulb. This idea gained further support from the discovery of Lewy pathology in the grafts of fetal mesencephalic brain tissue injected into patients with PD between the 1980s and 1990s. 16, 17 Neuronal grafts transplanted into transgenic mice overexpressing human a-synuclein have also shown a-synuclein inclusions within the graft. 18, 19 Moreover, Luk and colleagues 20 demonstrated that injection of synthetic a-synuclein fibrils into the dorsal striatum of wild-type non-transgenic mice led to cell-to-cell transmission of pathological a-synuclein and PD-like Lewy pathology in anatomically interconnected regions, further supporting the hypothesis that PD acts as a prion-like disorder. Although these propagation models have highlighted that a-synuclein is important in neuron degeneration, the mechanisms controlling the expression of a-synuclein are still not fully understood.
MicroRNAs (miRs) are a class of endogenous non-coding RNAs that regulate gene expression in a sequence-specific manner. [21] [22] [23] [24] They are single stranded and approximately 17-24 bases long. Aberrant miR activity has been associated with a number of neurodegenerative diseases including PD. [25] [26] [27] [28] In particular, miR-7 has been shown to bind to the 3 0 UTR of the SNCA gene and inhibit its translation. 29, 30 However, the pathophysiological relevance of the miR-7 targeting of SNCA to PD remains unclear. 31 In 2007, a method to study miRs was developed by Ebert and colleagues. 32 This involved the generation of a target sequence complementary to the miR of interest that contained multiple miR binding sites and, therefore, acted as a decoy/sponge by sequestering the endogenous miR. 32 Here, we use this miR sponge model in in vitro and in vivo systems and show that downregulation of miR-7 results in an upregulation of a-synuclein, dopaminergic neuron loss, and a loss of striatal dopamine.
RESULTS

miR-7 Levels Are Significantly Reduced in the Substantia Nigra Pars Compacta of Patients with PD
To investigate whether a decrease in miR-7 could contribute to the increase in a-synuclein in PD patients, we collected nigral sections taken from human postmortem brain samples from six patients with PD and five age-matched healthy controls ( Figure S1 ). The PD subjects studied were 71-87 years of age and were all taking a combination of Levodopa (L-DOPA) medications. Neuropathological examination performed by the UK Parkinson's Disease Society Tissue Bank revealed a-synucleinopathy, which was brainstem predominant and consistent with a clinical diagnosis of PD. Immunofluorescence staining also revealed accumulation and aggregation of a-synuclein in the brain sections taken from PD patients compared with healthy age-matched controls ( Figure 1A ). Furthermore, real-time qPCR analysis showed a significant reduction in the levels of mature miR-7 in PD patients compared with the healthy age-matched controls (p < 0.05) ( Figures 1B and 1C) , suggesting that miR-7 may play an important role in the increase of a-synuclein in PD patients.
miR-7 Regulates a-Synuclein Expression In Vitro
To explore the role of miR-7 in the neurodegenerative process of PD, we generated two lentiviral vectors, miR-7-GFP and miR-7T-AsRed Figure 1 . miR-7 Levels Are Significantly Decreased in the Nigra of Patients with PD (A) Representative images of a-synuclein staining (green) and nuclear counterstain (blue) in a PD brain section compared with a healthy age-matched control. Scale bar, 60 mm. Zoomed-in images are from boxed region. (B) RNA was extracted using the mirVana miR isolation kit from frozen nigral sections collected from six patients with PD and five healthy age-matched controls. miR-7 levels were detected by qPCR using a TaqMan miR-7 assay. miR-7 levels were significantly decreased in the PD patients compared with the healthy controls. Data were analyzed using an unpaired t test and expressed as mean ± SEM. *p < 0.05 for difference between PD and control samples. (C) Age range of the six patients with PD and five healthy age-matched controls. PD, Parkinson's disease.
( Figures S2-S4 ). To confirm effective miR-7 knockdown by the miR-7T-AsRed lentiviral vector, we co-transduced HEK293T cells with miR-7T-AsRed (MOI 2) and with varying MOIs of the miR-7-GFP lentiviral vector (0, 0.1, 1, and 5). Results show that an increase in miR-7 levels (mirrored by GFP expression) causes a decrease in the expression of the target sequence (indicated by AsRed expression) (Figure S5A) . At protein level, AsRed expression was completely abolished at MOIs of 1, 5, and 10 of the miR-7-GFP lentiviral vector (p < 0.001) ( Figures S5B and S5C ), confirming that miR-7 can bind to the target sequence resulting in protein knockdown in vitro. miRanda software was used to examine the potential interaction between miR-7 and the mouse snca gene. Three strong binding sites for miR-7 were found in the snca 3 0 UTR ( Figure S6 ). The top predictive binding site was related to the seed sequence (119-127nt), which is highly conserved, highlighting the evolutionary importance of miR-7 in snca regulation ( Figure S7A ).
To confirm this association, we cloned the full-length 3 0 UTR of the mouse snca gene into a luciferase vector downstream of a firefly luciferase reporter ( Figure S7B ). HEK293T cells were co-transfected with the 3 0 UTR snca plasmid with either the miR-7-GFP plasmid, a control CMV-GFP plasmid, or a control miR-449-GFP plasmid. An internal control plasmid (Renilla luciferase) was also co-transfected to correct for differences in transfection efficiency. miR-7-GFP decreased luciferase activity by approximately 44% (p < 0.05), confirming that miR-7 can bind to the 3 0 UTR of the snca gene and inhibit its translation. This effect was specific to miR-7, because miR-449-GFP had no effect on luciferase activity ( Figure S7C ). To confirm that miR-7 regulates a-synuclein expression, we transduced HEK293T cells with the miR-7-GFP or miR-7T-AsRed vectors (MOI 0, 0.1, 1 and 5). miR-7-GFP significantly decreased a-synuclein expression in a dose-dependent fashion (61% at an MOI of 5; p < 0.05) (Figures 2A and 2B) , whereas miR-7T-AsRed significantly www.moleculartherapy.org increased a-synuclein expression by 513% at an MOI of 5 (**p < 0.01) ( Figures 2C and 2D ).
miR-7 Knockdown Induces a-Synuclein Overexpression in the SNpc
We next tested our miR-7T-AsRed lentiviral vector in vivo. To titrate the amount of tissue transduced, we compared a single injection site with a double injection site in the mouse substantia nigra pars compacta (SNpc) ( Figure S8 ). We found that a single injection site of the miR-7T-AsRed into the SNpc was not sufficient to induce a significant upregulation of a-synuclein expression by 16 or 24 weeks (Figure S9A) . However, the number of tyrosine hydroxylase (TH)-positive neurons in the injected SNpc was decreased by 27% at 24 weeks postinjection, when compared with the control hemisphere ( Figures S9B  and S9C ). Behavioral analysis showed no signs of motor impairments ( Figures S9D and S9E) , and high-performance liquid chromatography (HPLC) analysis revealed no significant difference in the striatal levels of dopamine (DA) or its metabolites 3, 4-hydroxyphenylacetic acid (DOPAC) or homovanillic acid (HVA) (Figures S10A-S10C ). In contrast, animals that had a unilateral double injection showed a moderate increase in a-synuclein expression at 16 weeks, with further accumulation at 24 weeks (p < 0.05) ( Figures 3A and 3B ). This effect was specific to miR-7T overexpression because animals injected with a control CMV-AsRed lentiviral vector showed no change in a-synuclein levels ( Figure 3B ). Given that a double-site miR-7T injection was able to target a larger SNpc area leading to a-synuclein overexpression, this approach was used in subsequent studies. Oligomeric forms of a-synuclein are known to play an important role in the pathology of PD. 33 Therefore, to establish whether the unilateral double injection of the miR-7T vector also increased the oligomerization of a-synuclein, we used a proximity ligation assay (PLA) to detect a-synuclein oligomers. a-Synuclein-PLA has been shown to preferentially label oligomers compared with monomers and fibrils (Figures S11A and S11B). 34 The number of a-synuclein-PLA puncta was quantified in the injected SNpc and contralateral non-injected SNpc in miR-7T injected animals from the 24-week post-surgery cohort. miR-7T increased the a-synuclein-PLA signal by 50% compared with the control non-injected SNpc ( Figures 3C and 3D ). Furthermore, control animals injected with the CMV-AsRed vector showed no difference in PLA signal (Figure 3E) , illustrating that the miR-7T is causing an accumulation and aggregation of a-synuclein in vivo.
miR-7 Knockdown Causes TH Cell Loss in the SNpc and Reduction in Striatal DA
The number of TH-positive neurons was quantified in both the injected SNpc and contralateral non-injected SNpc to determine whether overexpression of miR-7T-AsRed could induce dopaminergic neuron death in the SNpc. The number of TH neurons in the miR-7T-AsRed-injected SNpc was significantly decreased by 39% at 16 weeks and by 73% at 24 weeks post-injection (p < 0.05) ( Figures 4A and 4B ). No significant difference in TH expression was found in control CMV-AsRed-injected animals ( Figure 4C ), indicating that the reduction in TH-positive neurons is due to miR-7T expression. However, HPLC analyses detected only a small difference in striatal DA and HVA levels at 24 weeks post-surgery (p < 0.05) ( Figures 5A-5C ), which was not consistent with the profound loss of dopaminergic neurons. Therefore, to detect whether this decrease in TH expression was due to cell death or a downregulation of activity, we also stained nigral sections from the 24-week cohort for vesicular monoamine transporter 2 (VMAT2), which is needed to transport monoamines (including DA) into synaptic vesicles. 35 The number of VMAT2-positive neurons was decreased by approximately 30% in the miR-7T-injected SNpc compared with the contralateral noninjected SNpc (Figures 5D and S11C), suggesting that although there was some cell death, many of the dopaminergic neurons had downregulated their activity accounting for the profound loss of TH expression.
Overexpression of miR-7T-AsRed Is Not Sufficient to Induce Locomotor Deficits
To establish whether overexpression of the miR-7T-AsRed lentiviral vector could induce PD-like motor impairment, we carried out behavioral analyses. Locomotor activity and amphetamine-induced rotations of the 24-week miR-7T-AsRed and control-injected animals were measured at 2, 10, and 20 weeks post-surgery. There was no significant difference in locomotor activity ( Figures 6A and 6B ) or in the number of amphetamine-induced rotations ( Figures 6C-6E) after injection of the miR-7T lentiviral vector at any of the three time points compared with the control animals, indicating that the loss of dopaminergic neurons and striatal DA was not sufficient to induce a behavioral phenotype. Interestingly, there was a trend toward a decrease in distance moved and velocity, as well as an increase in the number of amphetamine-induced rotations in the miR-7T-AsRed-injected animals compared with the control animals ( Figures 6A-6E) , suggesting that the development of motor deficits in this model requires more than the 24 weeks analyzed in this study.
DISCUSSION
Non-coding regions of the genome such as miRs have been suggested to play a vital role in the pathological mechanisms underlying PD. In 2009, Junn and colleagues 29 showed that miR-7 could bind to the 3 0 UTR of the SNCA gene between bases 119 and 127 and inhibit its translation in a dose-dependent manner. Because this sequence is conserved across several species, it was suggested that miR-7 might play a critical evolutionary role in the regulation of a-synuclein.
29,30
Here, we have shown that miR-7 levels are decreased in the nigra of patients with PD compared with age-matched healthy controls, www.moleculartherapy.org further suggesting that miR-7 may play an important role in regulating a-synuclein expression.
Increased expression and aggregation of a-synuclein is a basic hallmark of PD, along with the progressive loss of nigral DA neurons. Therefore, in this study, we wanted to investigate whether depletion of functional nigral miR-7 could provide a novel model to study the pathophysiology of PD. Using an miR-7-GFP-expressing lentiviral vector, we confirmed the binding between miR-7 and the 3 0 UTR of the mouse snca gene and showed that miR-7 inhibits its expression, resulting in a functional knockdown of a-synuclein protein. Furthermore, we have shown that the miR-7 target sequence (miR-7T-AsRed) competes for the miR-7 sequence in vitro and in vivo, resulting in a loss of function and an increase in a-synuclein protein expression.
Upregulation of a-synuclein expression has been increasingly linked to neuronal loss in PD. 4, 5, [11] [12] [13] [14] However, there has been much controversy about the form of a-synuclein that could be toxic to neurons. Oligomers of a-synuclein, as well as truncations and post-translational modifications, have been shown to play an important role in neuronal toxicity. 36 Using the new method PLA to detect a-synuclein oligomers, 34 we have shown that the miR-7T-AsRed target vector not only affects the monomeric form of a-synuclein, but also increases its oligomerization, thereby mirroring the pathology seen in patients with PD.
Mice injected with the miR-7T-AsRed lentiviral vector had a loss of nigral dopaminergic neurons and a decrease in striatal DA, both of which are characteristics of PD pathology and have been linked to upregulation of a-synuclein. Lentiviral vectors expressing human wild-type or mutant forms of a-synuclein have been shown to lead to a progressive loss of nigral dopaminergic neurons by 24%-35% in rats over 5 months, 37 whereas adenoviruses expressing human a-synuclein have been shown to decrease nigral dopaminergic neurons by up to 80% in as short as 6 weeks; however, these results are less consistent. 11, 12, [38] [39] [40] [41] In our model, miR-7T-AsRed significantly reduced TH expression by one-third at week 16 and two-thirds at week 24. However, staining with VMAT2, another neuronal marker, showed that there was only a 30% loss of neurons at 24 weeks, suggesting that the nigral neurons had downregulated their activity. This was consistent with the miR-7T-injected animals showing only a small deficit in striatal DA production, as well as being comparable with other animal models using lentiviral vectors expressing a-synuclein. Downregulation of TH activity has previously been reported after overexpression of human a-synuclein as a protective mechanism of the cell. 38 Interestingly, aggregated human a-synuclein has also been shown to reduce TH activity in dopaminergic neurons. 42 As miRs have many targets, it is impossible to rule out that miR-7 may be affecting TH expression and dopaminergic neuronal health via another method other than upregulation of a-synuclein. The absence of strong binding sites for miR-7 in the TH 3 0 UTR (data not shown) suggests that miR-7 does not affect TH expression directly, but an interesting future experiment would be to look at miR-7T in an a-synuclein knockout animal. This would conclude whether the downregulation of TH activity and loss of nigral neurons in our mouse model are indeed a consequence of the increase in accumulation and oligomerization of a-synuclein.
miR-7T-AsRed-injected animals displayed a trend toward decreased LMA and increased amphetamine-induced rotations compared with control animals, but these effects were not found to be significant, suggesting that the dopaminergic neuron loss was not sufficient to cause a major loss of striatal DA and thereby motor deficit at the time points studied. It is, however, known that the nigro-striatal system has remarkable plasticity because patients only present clinically with motor symptoms once their striatal DA levels have decreased by approximately 70%. 43 In addition, previous studies have shown that motor impairments only appear in animals with more than 50%-60% loss of nigral neurons, thus explaining the lack of motor impairment in our model. 38, 44, 45 Kim and colleagues 46 found that deleting Dicer in murine embryonic stem cell (ESC) lines led to a near-complete loss of production of dopaminergic neurons. Concurrently, mice lacking Dicer in postmitotic dopaminergic neurons developed a 90% loss of midbrain dopaminergic neurons after 8 weeks, suggesting that miRs play an important role in neurodegeneration. 46 This loss of dopaminergic neurons is significantly higher than in our study. However, Dicer loss of function will result in the incomplete processing of all miRNAs including all those miRNAs with a specific role in dopaminergic neuron metabolism. Increased miR binding sites or using imperfect complementary binding sites within the sponge target vector is correlated with increased inhibition of the target miRNA's function. 32, 47, 48 Although the miR-7T-AsRed target vector used in our model was sufficient to induce a-synuclein accumulation and aggregation, it might be that increasing the number of miR-7 decoy binding sites or using a miR-7 knockout would result in a higher level of nigral degeneration.
Kim and colleagues 46 found that miR-133b regulates the maturation and function of midbrain dopaminergic neurons and is deficient in the midbrain tissue of patients with PD. Furthermore, expression of miR-133b has been shown to prevent 1-methyl-4-phenylpyridinium (MPP) + toxicity in dopaminergic neurons and to inhibit a-synuclein expression in vitro. 49 miR-34b/c has also been predicted to target the 3 0 UTR of the SNCA gene and has been coupled to a decrease in the expression of DJ1 and Parkin, two proteins found to be important in familial forms of PD. 28, 50 In addition, miR-205 has been shown to regulate leucine-rich repeat kinase (LRRK2), another protein linked to sporadic and familial forms of PD. 51 miR-34b/c and miR-205 also have decreased expression in patients with PD, further suggesting an important role for miRs in the pathology of PD. 51 This study reveals that miR-7 is also deficient in the dopaminergic neurons of patients with PD. GWAS data have shown that several polymorphisms of the SNCA gene associated with an increased risk of developing PD are found in the 3 0 UTR. These polymorphisms could affect miR binding sites and cause dysregulation of SNCA expression. 6 Furthermore, miR-7 has been shown to be neuroprotective against impaired proteasome function and cytotoxicity caused by overexpression of www.moleculartherapy.org a-synuclein in vitro, as well as against toxins such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). 29, 52, 53 In addition, toxicity studies using MPTP in dopaminergic neuronal SH-SY5Y cells resulted in a 40% increase in a-synuclein mRNA levels and an equivalent decrease in miR-7 levels. 29 a-Synuclein expression also increases following inhibition of miR-7 in vitro, 30 further suggesting that miR-7 may provide a candidate therapeutic target for modulating a-synuclein levels in PD.
Conclusions
In conclusion, we have recapitulated key pathological hallmarks of PD by injecting the miR-7 decoy lentiviral vector into the SNpc of mice. We found increased a-synuclein expression and oligomerization, dopaminergic neuron death, and a reduction in striatal DA. Furthermore, in human nigral samples from patients with PD, we report decreased miR-7 levels compared with healthy age-matched controls. Our data highlight the significance of the evolutionary conserved regulation of a-synuclein by miR-7 and the importance of this miR for dopaminergic cell biology. Moreover, they provide a model to study the pathology of PD and to develop novel therapeutic interventions.
MATERIALS AND METHODS
Real-Time qPCR Analysis of miR-7 Levels in the Nigra of Patients with PD
Nigral sections were obtained from six patients with a clinical diagnosis of PD and five age-matched healthy controls from the UK Parkinson's Disease Society Tissue Bank at Imperial College London, UK. To quantify the expression of miR-7 in these frozen nigral sections, we extracted RNA using the mirVana miR isolation kit (Thermo Fisher) according to the manufacturer's instructions. A TaqMan microRNA-7 (miR-7) assay (Applied Biosystems) was used to detect and quantify miR-7 in these RNA by qPCR.
Generation of miR-7-and miR-7T-Expressing Lentiviral Vectors
An miR-7 lentiviral vector was generated using high-fidelity PCR to amplify the mouse miR-7-a1 (MIMAT0000677) sequence using a forward (5 0 -ACG TTC TAG ACC TTA ACC AAG CAA ACT TC-3 0 ) and reverse primer (5 0 -CGA TGG ATC CAA TGA AAC TGG AAG CTG-3 0 ). The sequence was then cloned into the lentiviral vector backbone pRRL-sincppt.CMV-GFP.wpre upstream of the GFP reporter tag. To produce the miR-7 target sequence (miR-7T), we designed a four times repeated sequence complementary to the miR-7 to compete for the miR-7 binding site. TTG GAA GAC TAG TGA TTT  TGT TGT ATC GTG GAA GAC TAG TGA TTT TGT TGT TTA  T-3 0 ; and antisense 2 strand: 5 0 -TGG AAG ACT AGT GAT TTT GTT GTG TGA TGG AAG ACT AGT GAT TTT GTT GTA CGC G-3 0 ) were annealed together by heating to 95 C for 5 min and then cooling for 1 hr. The target sequence was then cloned into the lentiviral vector backbone pRRL-sincppt.CMV-AsRed.wpre downstream of the AsRed reporter tag. Viral titers were determined using fluorescence-activated cell sorting (FACSCalibur; BD).
HEK293T Cell Culture and Transductions
Lentiviral vector production and validation were performed in the human embryonic kidney cells, bearing the large T antigen of SV40 virus immortalized cell line (HEK293T). The cells were maintained in DMEM (Sigma) supplemented with 10% fetal bovine serum (FBS; Sigma), 2 mM L-glutamine, 100 U/mL penicillin, 100 mg/mL streptomycin, and 1Â non-essential amino acids. HEK293T cells were seeded at 7.5 Â 10 4 cells/well in a 12-well plate 24 hr prior to transduction with lentiviral vectors. The lentiviral vectors at different MOIs were added to the wells in a reduced culture volume (500 mL). After 3-4 hr, the volume was increased to 1 mL and the cells incubated at 37 C for 48 hr. Transduced cells were visualized using a fluorescence and bright-field microscope (Leica DMRB). If cell nuclear staining was needed, 1 mg/mL Hoechst was added to the cells before imaging.
Generation of the 3
0 UTR of the snca Gene and Luciferase Assay A luciferase assay was performed to investigate whether miR-7 was binding to the 3 0 UTR of the snca gene. The mRNA sequence of the 3 0 UTR of the mouse snca gene (NCBI: NM_001042451.2) and the binding sites of miR-7 were confirmed using Miranda software (miR Target Scanning Algorithm). A forward (5 0 -CCG CTC GAG AAT GTC ATT GCA CCC AAT CT-3 0 ) and reverse primer (5 0 -CCC AAG CTT GGT GCA TAG TCT CAT GCT CACA-3 0 ) was then used to clone the 3 0 UTR sequence into the luciferase backbone vector pMIR-Tac-1Reprot-Luc. HEK293T cells were plated in a 24-well plate (4.0 Â 10 4 cells/well) in 500 mL of media 24 hr prior to transfection. HEK293T cells were co-transfected using FuGENE transfection 6 reagent (Promega) with 100 ng of the snca gene 3 0 UTR plasmid and an internal control Renilla Luciferase plasmid (pRL-SV40; Promega) in the presence of either 300 ng of the miR-7-GFP-expressing plasmid or a control plasmid (miR-449-GFP or GFP). The cells were then lysed and luciferase activity measured using a dual-luciferase assay kit (Promega) and a luminometer (Glomax multi+; Promega). Renilla activity was used to normalize luciferase activity to account for any difference in transfection efficiency between the conditions. Three independent experiments were performed.
Animals
The present study was conducted in adult male C57BL/6J mice (Harlan, UK) weighing between 20 and 30 g. All animals were housed in individually ventilated cages (IVCs) with free access to food and water, under standard conditions (six animals per IVC cage, 7:00 a.m. to 7:00 p.m. light phase, constant temperature and humidity). All procedures were carried out with the approval of Lilly Ethical Review Board and in accordance to UK Home Office regulations.
Stereotactic Surgery
To determine whether the miR-7T-AsRed lentiviral vector could cause overexpression of a-synuclein protein and produce PD pathology in vivo, we completed two experiments. The first experiment involved stereotactic injection of 2 mL of the miR-7T-AsRed lentiviral vector . The miR-7T-AsRed-injected animals were again left for 16 and 24 weeks, with some used for immunohistochemistry and others used for biochemical analyses. The 24-week cohort was also subject to behavioral analyses at 2, 10, and 20 weeks post-surgery. A control group of mice received two injections of the control CMV-AsRed lentiviral vector and were left for the full 24 weeks for biochemical analysis with behavioral analyses carried out at 2, 10, and 20 weeks post-surgery.
Locomotor Activity LMA was measured in complete darkness in clear Perspex boxes (40 Â 40 Â 30 cm 3 ; Eli Lilly) based on infrared fields. Four boxes were placed on each field, which were monitored using overhead infrared cameras. The cameras input data into a computer via a Quad compressor unit. The image analysis application Ethovision www.moleculartherapy.org (Noldus Information Technology, the Netherlands) digitized the path made by animals and used this to calculate various parameters, such as distance moved, velocity, and number of rotations. Mice were weighed and placed in the LMA boxes. Exploratory behavior was assessed for 30 min. Following this, they were dosed with 2.5 mg/kg D-amphetamine sulfate (A-5880 LY2800792; Sigma) by intraperitoneal (i.p.) injection. LMA was assessed for a further 90 min. When the experiment was complete, the data were analyzed using Microsoft Excel, and the total distance moved (cm), velocity (cm/s), and ipsilateral rotations were calculated for each animal.
Dissection of Striatal and Nigral Tissue
For biochemical analysis, animals were culled by schedule 1, and their brains were removed and placed on ice. The striatum (ST) and substantia nigra (SN) from the right and left hemisphere were removed using a mouse matrix (Zivic Instruments, USA). The ST sections were weighed and transferred onto dry ice before being stored at À80
C for HPLC analysis. The SN sections were processed for western blotting analysis.
Transcardial Perfusions
For immunofluorescence analysis, animals were terminally anesthetized with 200 mg/kg i.p. pentobarbital sodium (Ayrton Suader, UK) before transcardial perfusions were performed through the ascending aorta using PBS followed by 4% paraformaldehyde (PFA) (Sigma). The animals were then decapitated, and the brain was removed and post-fixed in 4% PFA at 4 C for 24 hr. The following day, the brain was immersed in 30% sucrose (Sigma) solution for at least 24 hr.
Sectioning Tissue Using a Cryostat
Before brains were sectioned, they were snap-frozen using isopentane (Fisher Scientific) and dry ice. Brains were stored at À80 C until ready to use. Brains were mounted into OCT mounting matrix (Fisher Scientific) and placed in a À20 C Leica CM190 Cryostat, and 20 mm coronal sections were prepared. These were transferred onto glass slides (Thermo Scientific) and air-dried before storing at 4 C.
Immunofluorescent Staining of Mouse Brain Sections
Non-specific binding was blocked using 10% normal goat serum (Vector Labs) diluted in 0.1% Triton X-100/PBS (blocking solution) and left to incubate overnight at 4 C. Sections were transferred to primary antibody solution (either TH [ab152; Millipore] or VMAT2 [ab81855; Abcam] in blocking solution) and incubated overnight at 4 C. The secondary antibody (Alexa Fluor 488; A11008; Invitrogen) diluted in blocking solution was then added and incubated for 1 hr at room temperature. If required, cell nuclei were counterstained with 1 mg/mL Hoechst. The slides were mounted in PBS and glycerol (1:1; Sigma) and imaged using a fluorescence microscope (Leica DMRB). The number of TH/VMAT2-positive cells was counted in the injected and control/non-injected SN in three sections per mouse at the site of injection using ImageJ and the "cell counter" plug-in.
Immunofluorescent Staining of Human Brain Sections
Fresh-frozen sections were fixed with ice-cold methanol for 20 min at À20 C. Non-specific binding was blocked using 10% normal goat serum (Vector Labs) diluted in 0.1% Triton X-100/PBS. Primary a-synuclein antibody (610787; BD Biosciences) (1:100) was incubated overnight at 4 C. Sections were washed (Â3) and incubated in anti-mouse Alexa 488 for 2 hr at room temperature. Sections were washed (Â3) and nuclei stained with Hoechst. Sections were mounted in PBS/glycerol and imaged using a fluorescent microscope (Leica DMRB).
PLA a-Synuclein PLA experiments were carried out using Duolink kits supplied by Sigma according to the manufacturer's instructions. Briefly, the conjugates were prepared with the anti-a-synuclein 4D6 antibody (ab1903; Abcam) as previously described. 34 20-mm-thick coronal sections were dried at 37 C, immersed in PBS, and then antigen retrieved in citrate buffer (pH 6) (93678; Abcam) by microwave heating for a total of 10 min. All samples were incubated in Duolink block solution at 37 C for 1 hr, followed by the conjugates diluted in Duolink PLA diluent (1:2,000) overnight at 4 C. After washing in TBS + 0.05% Tween 20, samples were incubated with Duolink ligation solutions and ligase for 1 hr at 37 C, before washing and incubation with Duolink amplification reagents and polymerase for 2.5 hr at 37 C. Samples were then washed in TBS in the dark and counterstained and mounted with FluorSave (Merck). Preparation and analysis of a-synuclein fibrils were carried out as previously described. 34 After preparation, samples were centrifuged at 13,000 Â g for 10 min; the supernatant was taken as oligomeric fraction, and the precipitate was taken as fibrillar fraction. PLA and electron microscopy were performed as previously described. 34 Quantitation of the PLA signal was performed averaging four blinded random fields per sample at 20Â magnification on an EVOS flAUTO (Thermo Scientific) and counting the resulting puncta on ImageJ.
HPLC Analysis
Striatal samples were sonicated for 10 s in 500 mL of ice-cold homogenizing buffer (0.1 M perchloric acid, 0.1 mM EDTA, 2.5 mg/L ascorbate). The samples were then centrifuged at 20,000 Â g for 15 min at 4 C. The supernatant was collected and filtered through a syringeless filtration device (UniPrep), and samples were stored at À80 C until use. 20 mL of the supernatant was analyzed by HPLC to detect DA and its metabolites DOPAC and HVA. The HPLC system consisted of a Jasco HPLC pump, triathlon autosampler (Spark Holland), and BAS LC4C detector (BAS Analytical) coupled to an Empower data system (Waters). To separate the samples, we used a Hypersil BDS column (150 Â 3.0 mm C18 3u). The mobile phase (pH 2.8) consisted of 0.1 M monosodium phosphate (Fisher), 350 mg/L octanesulfonic acid (Fisher), and 14% methanol, and the flow rate was set to 400 mL/min with a column oven temperature of 40 C. Oxidation settings were +775 mV, 20 nA/V, whereas the reduction settings were +50 mV, 10 nA/V.
Immunoblotting
Protein samples were isolated from HEK293T cells or brain tissue using radioimmunoprecipitation assay (RIPA) lysis buffer (1% Igepal CA-630 [Sigma], 0.5% sodium deoxycholate [BDH Laboratories Supplies], and 0.1% SDS [Sigma] in PBS) supplemented with 1Â protease inhibitor (Complete Mini; Roche). Protein levels were determined using a bicinchoninic acid (BCA) assay (Pierce, Thermo Scientific). Proteins (10-50 mg) were resolved by SDS-PAGE, transferred onto polyvinylidene difluoride (PVDF) membrane, and incubated with primary antibodies as follows: AsRed (1:500; Clontech), a-synuclein (1:500, 610786; BD), and TH (1:1,000, ab81855; Abcam). Horseradish peroxidase (HRP)-conjugated secondary antibodies (1:5,000-10,000) were added and proteins visualized using enhanced chemiluminescence (34080; Pierce). a-Tubulin (1:2,000 T9026; Sigma) was used as a protein loading control.
Data Handling and Statistical Analysis
Statistical analysis was performed using GraphPad Prism 5.0 software (GraphPad Software, CA, USA). For in vivo experiments, all data were normalized to a mean of all of the control hemispheres for every animal within that time point. Student t tests were used when only two groups were analyzed. For more than two groups and only one factor as the source of variance, a one-way ANOVA was used followed by an appropriate post hoc test. For more than two groups with more than one factor as the source of variance, a two-way ANOVA was used followed by a Bonferroni post hoc test. The figures show the mean ± SEM with p < 0.05 accepted as statistically significant.
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